Related Experiment Video

Updated: May 14, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

Familial hypercholesterolemia affects microvascular autoregulation in children

Oliver Schlager1, Kurt Widhalm, Alexandra Hammer

  • 1Department of Medicine II, Division of Angiology, Medical University of Vienna, Austria.

Metabolism: Clinical and Experimental
|January 30, 2013
PubMed

Insights

Familial hypercholesterolemia (FH) affects microvascular blood flow regulation in children. This study found altered post-occlusive reactive hyperemia (PORH) in children with FH, indicating impaired microvascular function from a young age.

Area of Science:

  • Pediatric Cardiology
  • Vascular Biology
  • Metabolic Disorders

Background:

  • Familial hypercholesterolemia (FH) is known to impair macrovascular endothelial function in children, increasing future cardiovascular risk.
  • The impact of FH on microvascular function in pediatric populations remains largely unexplored.
  • Understanding microvascular autoregulation is crucial for assessing early cardiovascular health in children with FH.

Purpose of the Study:

  • To investigate the effects of Familial hypercholesterolemia (FH) on microvascular autoregulation in children.
  • To utilize post-occlusive reactive hyperemia (PORH) as a method to assess microvascular function in pediatric FH.
  • To determine if microvascular dysfunction is present in children diagnosed with FH.

Main Methods:

  • Post-occlusive reactive hyperemia (PORH) of the skin was measured using laser Doppler fluxmetry.
  • Key parameters assessed included baseline perfusion, biological zero, peak perfusion, time to peak, and recovery time.
  • The study included 16 children diagnosed with FH and 91 healthy controls.

Main Results:

  • Children with FH exhibited higher peak perfusion and longer recovery times compared to controls.
  • A lower biological zero was observed in children with FH, suggesting altered microvascular tone.
  • No significant differences were found in baseline perfusion or time to peak perfusion between the groups.

Conclusions:

  • This study provides the first evidence of impaired microvascular autoregulation in children with Familial hypercholesterolemia (FH).
  • The observed differences in PORH indicate that microvascular blood flow regulation is affected in pediatric FH.
  • These findings suggest that microvascular dysfunction associated with FH begins in childhood.
Abstract

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Autoregulation of Blood Flow01:17

Autoregulation of Blood Flow

Autoregulation mechanisms are characterized by their inherent capacity for self-regulation without necessitating specific nervous stimulation or endocrine control. These mechanisms facilitate the adjustment of blood flow and, therefore, perfusion specific to each tissue region. This self-regulation encompasses chemical signals and myogenic controls.
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation.
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...